Ratings Dis-Chem Pharmacies Limited

Equities

DCP

ZAE000227831

End-of-day quote Johannesburg S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
30.62 ^ZAR	-0.13%		-2.30%	-0.23%

Feb. 23	South Africa's Dis-Chem sales rise 12.2% on strong retail revenue	RE
Feb. 23	Dis-Chem Pharmacies Limited Announces Group Revenue Results for the Period from 1 September 2023 to 28 January 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

With regards to fundamentals, the enterprise value to sales ratio is at 0.82 for the current period. Therefore, the company is undervalued.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company does not generate enough profits, which is an alarming weak point.
The company benefits from high valuations in earnings multiples.
The company appears highly valued given the size of its balance sheet.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DIS-CHEM PHARMACIES LIMITED	-0.23%	1.37B		C
WALGREENS BOOTS ALLIANCE, INC.	-32.59%	15.36B		B-
JD HEALTH INTERNATIONAL INC.	-36.57%	10.16B		B
YIFENG PHARMACY CHAIN CO., LTD.	+9.54%	6.13B		C
MATSUKIYOCOCOKARA & CO.	-10.81%	6.01B		C+
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-35.14%	5.65B		B
NAHDI MEDICAL COMPANY	-0.88%	4.71B		D-
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+51.51%	4.33B	-	C
CLICKS GROUP LIMITED	-11.96%	3.58B		B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-16.75%	3.21B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes